Phathom Pharmaceuticals Business Summary

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of novel treatments for gastrointestinal (GI) diseases. The company generates revenue primarily through the direct sale of its lead product, VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (P-CAB) for which it holds exclusive rights in the U.S., Europe, and Canada. Its primary business segments are focused on acid-related disorders, with a portfolio that includes VOQUEZNA tablets for Erosive and Non-Erosive GERD and specialized Triple and Dual Paks for Helicobacter pylori infection. As of early 2026, Phathom has achieved significant commercial momentum, reporting FY2025 revenues of approximately $175 million and targeting operating profitability by the second half of 2026. The company competes directly with established proton pump inhibitor (PPI) giants such as AstraZeneca and Takeda, as well as biopharmaceutical peers like Viking Therapeutics and Kiniksa Pharmaceuticals, positioning itself as the primary clinical disruptor to the legacy PPI market. Phathom was co-founded by David Socks, Dr. Azmi Nabulsi, and the late Dr. Tachi Yamada, drawing on a deep heritage from Takeda Pharmaceuticals and Frazier Healthcare Partners. The current leadership team is headed by President and CEO Steven Basta, who was appointed in April 2025 and brings over 25 years of industry experience from SaNOtize, Mahana Therapeutics, and BioForm Medical. Chief Financial and Business Officer Sanjeev Narula, appointed in October 2025, provides extensive financial scaling expertise following his tenure as CFO of Intra-Cellular Therapies and Viatris. The company’s strategic direction is overseen by a board chaired by Michael Cola and supported by prominent institutional investors, including Frazier Life Sciences, Medicxi, Carlyle Group, and BlackRock, which maintain significant positions as the company transitions toward sustainable profitability.